THER (Theralink Technologies) Quality Rank

View and export this data going back to 2007. Start your Free Trial

What is Theralink Technologies Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Theralink Technologies Quality Rank Related Terms

Thank you for viewing the detailed overview of Theralink Technologies's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralink Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theralink Technologies Inc (OTCPK:THER) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401

Website

https://www.theralink.com

Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.

Executives

Danica Holley	director	7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Matthew Wilson Schwartz	director	15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401
Chilcott, Iii Thomas E.	officer: Chief Financial Officer	373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Jeffrey Busch	director	7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Yvonne Fors	director	1201 MONSTER RD SW STE 350, RENTON WA 98057
Michael I Ruxin	director, officer: Chief Executive Officer	HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184
Avant Diagnostics, Inc	10 percent owner	1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007
Brian Gill Barnett	officer: Chief Executive Officer	230 N SPRINGER, LOS ALTOS CA 94024
Robert Neal Holcomb	director	PO BOX 535, ROLLING FORK MS 39159
Volnie Carlos Fernando Alaman	10 percent owner, officer: Chief Operating Officer-Vitel	MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Odabachian Manuel Cosme	director, 10 percent owner, officer: Global Operations GM-Vitel	MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Daniel S. Hoverman	director	C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809
Rice Charles L Jr	director	C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk	director, officer: CFO & President	549 MILGATE PLACE, BATON ROUGE LA 70810
Jonathan Frederick Head	director, officer: Chief Executive Officer	6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817